Plasma concentrations of fluvoxamine and maprotiline in major depression: implications on therapeutic efficacy and side effects
- 1 March 1993
- journal article
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 3 (1), 13-21
- https://doi.org/10.1016/0924-977x(93)90290-3
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Comparative Efficacy of AntidepressantsDrugs, 1992
- Response to Total Sleep Deprivation Before and During Treatment with Fluvoxamine or Maprotiline in Patients with Major Depression - Results of a Double-Blind StudyPharmacopsychiatry, 1990
- Paroxetine plasma levels: lack of correlation with efficacy or adverse eventsActa Psychiatrica Scandinavica, 1989
- Paroxetine in the treatment of depression ‐ a randomized comparison with amitriptylineActa Psychiatrica Scandinavica, 1985
- Relationship between clinical effects, serum drug concentration and serotonin uptake inhibition in depressed patients treated with citalopramEuropean Journal of Clinical Pharmacology, 1985
- Double-Blind Comparison of Intravenous Versus Oral Maprotiline*. Antidepressant Activity, Plasma Levels, Side-EffectsPharmacopsychiatry, 1985
- Maprotiline in affective illnessJournal of Affective Disorders, 1983
- An Early Clinical Phase II Evaluation of Paroxetine, a New Potent and Selective 5HT-Uptake Inhibitor in Patients with Depressive IllnessPharmacopsychiatry, 1982
- Response to Maprotiline Treatment in Depressive Patients Relationship to Urinary MHPG Excretion and Plasma Drug LevelPharmacopsychiatry, 1982
- A double blind comparison of zimelidine and amitriptyline in endogenous depressionActa Psychiatrica Scandinavica, 1981